Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus

Brazilian Journal of Infectious Diseases

Volumn 9, Issue 3, 2005, Pages 191-200

  Machado, Adão R L ^a   Arns, Clovis Da Cunha ^a   Follador, Wilson ^a   Guerra, Aline ^a  

^a NONE

Author keywords

Cost; Linezolid; Pharmacoeconomic; Pneumonia; Staphylococcus aureus; Vancomycin; Ventilator

Indexed keywords

ANTIINFECTIVE AGENT; GENERIC DRUG; LINEZOLID; OXAZOLIDINONE DERIVATIVE; VANCOMYCIN;

ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA; REVIEW; SYSTEMATIC REVIEW;

EID: 27844463273     PISSN: 14138670     EISSN: 14138670     Source Type: Journal    
DOI: 10.1590/S1413-86702005000300001     Document Type: Review

References (48)

1. Leroy O., Soubrier S. Hospital-acquired pneumonia: risk factors, clinical features, management, and antibiotic resistance. Curr Opin Pulm Med 2004; 10:171-5.
2. Prade S.S., Oliveira S.T., Rodrigues R., et al. Estudo brasileiro de magnitude das infecções hospitalares em hospitals terciários. Rev Controle Infec Hosp 1995;2:11-24.
3. .Fernandes A.T., Zamorano P.O., Torezan Filho M.A. Pneumonia Hospitalar. In: Fernandes A.T., Fernandes M.O.V., Ribeiro Filho N Eds. Infecção Hospitalar e suas interfaces na área da saúde. Editora Atheneu, São Paulo. 2000.
4. Rello J., Ollendorf D.A., Oster G., et al. The VAP Outcomes Scientific Advisory Group. Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large US Database Chest 2002;122:2115-21.
5. Medeiros E.A.S. Efeito da pneumonia hospitalar sobre a letalidade e o tempo de hospitalização em adultos internados em unidade de terapia intensiva. São Paulo, 1991. 131p. MSc. thesis (Escola Paulista de Medicina).
6. Diekema D.J., Pfaller M.A., Schmilz F.J., et al. SENTRY Participants Group. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(Supp12):S114-32.
7. Sader H.S., Gales A.C., Pfaller M.A., et al. Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program. Braz J Infec Dis 2001;5:200-14.
8. Costa S.F., Newbauer M., Santos C.R., et al. Nosocomial pneumonia: importance of recognition of aetiological agents to define an appropriate initial empiric therapy. Int J Antimicrob Ag 2001;17:147-50.
9. Sadoyama G., Gontijo Filho P.P. Risk factors for methicillin resistant and sensitive Staphylococcus aureus infection in a Brazilian university hospital. Braz J Infect Dis 2000;4:135-43.
10. Dietrich E.S., Demmier M., Schulgen G., et al. Nosocomial pneumonia: a cost-of-illness analysis. Infection 2002;2(30):61-7.
11. Warren D.K., Shukla S.J., Olsen M.A., et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003;31:1312-7.
12. Kappstein I., Schulgen G., Beyer U., et al. Prolongation of hospital stay and extra costs due to ventilator-associated pneumonia in an intensive care unit. Eur J Clin Microbiol Infect Dis 1992;11:504-8.
13. Boyce J.M., Potter-Bynoe G., Dziobek L., Solomon S.L. Nosocomial pneumonia in Medicare patients. Hospital costs and reimbursement patterns under the prospective payment system. Arch Intern Med 1991;151:1109-14.
14. Haddadin A.S., Fappiano S.A., Lipsett P.A. Methicillin resistant S. aureus (MRSA) in the intensive care unit. Postgrad Med J 2002;78:385-92.
15. Kollef M.H., Sherman G., Ward S., et al. Inadequate antimicrobial treatment of Infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74.
16. Iregui M., Ward S., Sherman G. et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002,1222:262-8.
17. Höffken G., Niederman M.S. Nosocomial pneumonia: the importance of a deescalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002;122:2183-96.
18. Hubmayr R.D., Burchardi H., Elliot M., et al.: Statement of the 4th International Consensus Conference in Critical Care on ICU-Acquired Pneumonia - Chicago, Illinois, May 2002. Int Care Med 2002;28:1521-36.
19. Sandiumenge A., Diaz E., Bodi M., et al.: Therapy of ventilator- associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy." Int Care Med 2003;29:876-83.
20. Chopra I. Antibiotic resistance in Staphylococcus aureus: concerns, causes and cure. Expert Rev Anti-Infect Ther 2003;1(1):45-55.
21. Sandiumenge A., Diaz E., Bodi M., et al. Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy". Intensive Care Med 2003;29:876-83.
22. Cruciani M., Gatti G., Lazzarini L., et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996;35:865-71.
23. Goldstein F.W., Kitzis M.D. Vancomycin-resistant Staphylococcus aureus: no apocalypse now. Clin Microbiol Infect 2003;9:761-5.
24. Lamer C., De Beco V., Soler P., et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993;37:281-6.
25. Sakoulas G., Moise-Broder P.A., Schentag J., et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicr Agents Chemother 2004;42:2398-402.
26. González C., Rubio M., Romero-Vivas J., et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clinical Infectious Diseases 1999;29:1171-7.
27. Stevens D., Dotter B., Madara-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti-Infective Ther. 2004;2:51-9.
28. Perry C.M., Jarvis B. Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs 2001;61:525-51.
29. Kaatz G.W., Rybak M.J. Oxazolidinones: new players in the battle against multiply resistant Gram-positive bacteria. Emerg Drugs 2001;6:1-13.
30. Moellering Jr R.C. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003;138:135-42.
31. Stalker D.J., Jungbluth G.L., Hopkins N.K, et al. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemoth 2003;51:1239-46.
32. Gee T., Ellis R., Marshall G., et al. Pharmacokinetics and tissue presentation of linezolid following multiple oral doses. Antimicrob Ag Chemother 2001;45:1843-6.
33. Honeybourne D., Tobin C., Jevons G., Andrews J., Wise R. Intrapulmonary penetration of linezolid. J Antimicrob Chemother 2003;51:1431-4.
34. Conte Jr J.E., Golden J.A., Kipps J., et al. Intrapulmonary Pharmacokinetics of Linezolid. Antimicr Agents Chemother 2002;46:1475-80.
35. Rubinstein E., CammarataS., Oliphant T., et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: arandomized, doubleblind, multicenter study. Clin Infect Dis 2001;32:402-12.
36. Wunderink R.G., Cammarata S.K., Oliphant T.H., et al. Linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia: continuation of a randomized, double-blind, multicenter study. Clin Ther 2003;25:980-92.
37. Wunderink R.C., Rello J., Cammarata S., et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789-97.
38. Kollef M.H., Rello J., Cammarata S.K., et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004;30:388-94.
39. Guia de Preços Brasindice, edição 565 de 20 de Maio de 2004. São Paulo, Editora Andrei.
40. Perri M. Pharmacoconomics: A tool for clinical decision making. Pharmacoeconomics: Infect Dis 1998;2:2-4.
41. Vianna D., Mesquita E.T. Economia da saúde: ferramenta para a tomada de decisão em Medicina. Rev SOCERJ 2003;16:258-61.
42. Garcia E., Iversone L.B., Cyrillo D.C. Metodologia para determinar el costo de una efermedad: Algunos Indicadores de Costo. Revista del Institute de Higiene y medicina social 1998;2:37-42.
43. Drummond M.F. The use of health economic information by reimbursement authorities. Rheumatology 2003;42(suppl. 3):iii60-iii3.
44. Shah N.P., Redd P., Paladino J.A., et al. Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model. Current Medical Research and Opinion 2004;20:779-90.
45. Karam C.M., McKinnon P.S., Neuhauser M.M., Rybak M.J. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy 1999; 19:257-266 (Erratum, 19:674, 1999).
46. Felmingham D. Glycopeptides: vancomycin and teicoplanin. In Clinical Antimicrobial Assays (Reeves, D.S., Wise, R., Andrews, J.M. & White, L.O., Eds), pp. 137-48.1999. Oxford University Press, Oxford, UK.
47. MacGowan A.P., Reeves D.S., Wise, R. Interpretation of antimicrobial assays. In Clinical Antimicrobial Assays Reeves, D.S., Wise, R., Andrews, J.M. & White, L.O., Eds, pp. 1-9. 1999. Oxford University Press, Oxford, UK.
48. British National Formulary. British National Formulary, 2001, Vol. 42. British Medical Association and Royal Pharmaceutical Society of Great Britain, London, 2001, UK.